NeuroRestore

NeuroRestore occupies an academic-to-clinical position in neurotechnology rather than a conventional venture-backed medical-device profile. Its work spans spinal cord injury, Parkinson’s disease, stroke, traumatic brain injury, and paralysis, combining neuroscience, bioengineering, neurosurgery, and treatment delivery within one research and innovation center. In spinal neuromodulation, it operates in a field that includes ONWARD Medical, which is developing implantable stimulation systems for spinal cord injury, and Synchron and Neuralink, which focus more heavily on brain-computer interfaces. NeuroRestore’s differentiator is the breadth of its translational model: its portfolio includes brain-spine interfaces, spinal stimulation, gene therapy, neurorobotics, photoelectric neural implants, and electronic implants for autonomic regulation. Unlike a single-product commercial startup, it appears to function as a multidisciplinary research platform supported by philanthropic grants, including funding from the Christopher & Dana Reeve Foundation and Michael J. Fox Foundation. Its $3.6 million in disclosed grant funding suggests an early-stage, research-led capitalization profile.

NeuroRestore’s trajectory shows a progression from institution-building toward translational neurotechnology and clinical research. The organization was founded in 2019 and has developed a portfolio covering spinal stimulation, brain-spine interfaces, gene therapy, neurorobotics, and neural implants. Two grants announced in March and April 2024 provided $3.6 million in combined support, creating a meaningful funding base for an early-stage research institution. The March 2024 award from the Christopher & Dana Reeve Foundation was the larger grant at $2.6 million, followed by a $1 million Michael J. Fox Foundation grant in April. Its January 2025 mobility-focused announcement marked a public-facing inflection point, emphasizing therapies intended to help paralyzed patients walk again. The December 2024 attention around hypothalamic deep-brain stimulation further broadened the organization’s clinical relevance beyond spinal cord injury. Hiring activity in late 2025 for doctoral researchers, graduate students, and physiotherapy interns points to ongoing expansion of research and treatment capacity rather than a shift toward rapid commercial scaling. Key uncertainties remain: there is no disclosed valuation, revenue profile, regulatory timeline, or employee-growth series, and no additional funding after April 2024 is documented.